ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-12-18 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | PDF • 254.5 KB | ||
| 2018-12-06 07:00 |
Abivax erhalt DSMB-Empfehlung zur Fortsetzung der laufenden Erweiterungsstudie …
|
German | HTML • 19.6 KB | ||
| 2018-12-06 07:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | PDF • 288.5 KB | ||
| 2018-12-06 07:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | PDF • 288.5 KB | ||
| 2018-11-16 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | PDF • 256.2 KB | ||
| 2018-11-09 08:00 |
Abivax KOL event today in Paris on ABX464 therapeutic-candidate in mid-stage cl…
|
English | HTML • 10.2 KB | ||
| 2018-09-28 06:30 |
Abivax gibt Halbjahresergebnisse 2018 und Unternehmens-Update bekannt (News mit…
|
German | HTML • 35.8 KB | ||
| 2018-09-06 12:16 |
Abivax SA (ABVX-FR): Remarkable data opens door to $15bn IBD market
|
English | HTML • 17.2 KB | ||
| 2018-09-04 07:00 |
Abivax veroffentlicht beeindruckende Ergebnisse der klinischen Phase-2a-Studie …
|
German | HTML • 24.6 KB | ||
| 2018-07-26 08:00 |
ABIVAX prasentiert Daten zum Wirkmechanismus von ABX464 auf der 22. Internation…
|
German | HTML • 10.8 KB | ||
| 2018-07-25 08:00 |
ABIVAX sichert sich Fremdkapitalfinanzierung von bis zu EUR 20 Mio. von Kreos C…
|
German | HTML • 16.9 KB | ||
| 2018-07-24 08:00 |
Abivax sponsort Auszeichnung fur Projekte zur Heilung von HIV-Infektionen
|
German | HTML • 10.7 KB | ||
| 2018-07-19 08:00 |
ABIVAX gibt den Abschluss der Patientenbehandlung in klinischer Phase-2a-Proof-…
|
German | HTML • 11.1 KB | ||
| 2018-07-04 13:25 |
Abivax SA (ABVX-FR): ABX464 reduces HIV DNA in latent viral gut reservoir
|
English | HTML • 16.2 KB | ||
| 2018-07-03 08:00 |
ABIVAX berichtet positive Top-Line Ergebnisse aus Phase-2a-Studie mit ABX464 (A…
|
German | HTML • 10.3 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
